IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27 th Annual Global ...

Consider it your chance to have the first look at – and the last word on – all of Vogue’s content. Use precise geolocation ...

The mucus comes from the conjunctiva which is the transparent tissue covering the whites of the eye and internal surface of ...

Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...

You likely wash your face twice a day, and that's exactly what your dermatologist wants you to do. Having rosacea poses an ...

Q4 2024 Earnings Call Transcript February 25, 2025 Tarsus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Good morning and welcome to Tarsus this year in 2024 financial results conference call. As a reminder, this call is being recorded at this time. I would like to turn the call over to David Nakasone, ...

Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned ...

Continued to advance a robust pipeline. Pursuing the next potentially transformative category in eye care - Ocular Rosacea a ...

Artificial intelligence (AI) has increasingly become part of everyday life over the past decade. It is used for everything from personalising social media feeds to powering medical breakthroughs.